Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French Innovative Leukemia Organization (FILO)
Source: American Journal of Hematology - Category: Hematology Authors: Sophie Godet, Caroline Protin, Jehan Dupuis, Caroline Dartigeas, Jean ‐Noël Bastie, Charles Herbaux, Véronique Leblond, Sophie de Guibert, David Ghez, Annie Brion, Loïc Ysebaert, Alain Delmer, Anne Quinquenel Tags: Correspondence Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | France Health | Hematology | Leukemia | Study